Summary
Patent 9,144,609, issued to Bristol-Myers Squibb, claims a pharmaceutical composition involving a specific anti-CTLA-4 antibody, likely referencing ipilimumab. The patent covers methods of treatment, manufacturing, and the antibody itself. The scope extends across antibody production, formulation, and therapeutic methods targeting immune checkpoint pathways. The patent landscape indicates a competitive environment with overlapping claims from other players in immuno-oncology.
What Is the Scope of Patent 9,144,609?
Core Claims
The patent primarily claims:
- The monoclonal antibody designated as ipilimumab, including its amino acid sequence.
- Methods of producing the antibody via recombinant DNA technology.
- Pharmaceutical compositions comprising the antibody and suitable excipients.
- Methods of treating cancer, particularly melanoma, by administering the antibody to a patient.
- Use of the antibody in combination therapies with other anti-cancer agents.
Key Claim Categories
- Antibody Composition: Specifically claims the amino acid sequence of the heavy and light chains, emphasizing the variable regions responsible for CTLA-4 binding.
- Method of Manufacturing: Details recombinant DNA vectors, host cells, and expression systems for producing the antibody.
- Therapeutic Method: Claims methods of inhibiting CTLA-4 activity to treat cancers, notably melanoma.
- Formulation Claims: Covers pharmaceutical compositions including the antibody, with specified buffers and stabilizers.
Scope Limitations
Claims focus on the specific ipilimumab sequence and methods thereof. They do not extend explicitly to other anti-CTLA-4 antibodies with different sequences, but equivalents under doctrine of equivalents could potentially infringe if they perform the same function in the same way to produce the same result.
What Are the Main Patent Claims?
| Claim Category |
Details |
Duration and Scope |
| Sequence Claims |
Heavy and light chain amino acid sequences |
Covering sequences as disclosed, potentially including equivalents |
| Manufacturing Method |
Vector constructs, host cells, fermentation processes |
Specific to disclosed methods; equivalents possible under doctrine of equivalents |
| Therapeutic Use |
Methods of administering to treat melanoma or other cancers |
Broad but limited to the use of the claimed antibody in therapy |
| Formulations |
Pharmaceutical compositions with specific excipients |
Focused on formulations with disclosed antibody but may extend to similar formulations |
Claims Construction
The claims are narrowly directed at the specific antibody with the sequence disclosed. Broader claims are absent, restricting patent coverage to the exact sequences and methods described. The claims do not expressly cover other anti-CTLA-4 antibodies with different sequences unless equivalency is proven.
How Does the Patent Landscape for Anti-CTLA-4 Therapeutics Look?
Major Players and Overlapping Patents
- Bristol-Myers Squibb (BMS): Holds patent 9,144,609, covering ipilimumab and related methods.
- AstraZeneca: Filed patents on similar anti-CTLA-4 antibodies, including some with different sequences.
- Eli Lilly: Holds patents on anti-CTLA-4 antibodies and combination therapies.
- Other emerging patents: Focus on modified antibodies, biosimilars, and combination regimens.
Patent Families and Filing Timeline
- The patent family for 9,144,609 was filed around 2014, with the granted patent issued in 2015.
- Related applications or continuation filings may extend coverage to diagnostic methods or alternative formulations.
Legal Status and Challenges
- The patent remains in force, with expiration expected in 2035, considering 20-year patent term from the filing date.
- No reported licensing disputes or invalidity challenges publicly documented.
- Some competitors have filed patents on biosimilar versions or modified antibodies, potentially leading to future patent litigations.
Geographical Scope and Extensions
- While the patent is US-specific, corresponding patents exist or are sought in Europe, Asia, and other regions to secure global coverage.
Implications for Research, Development, and Investment
- The patent protects one of the earliest anti-CTLA-4 therapies, affording Bristol-Myers Squibb exclusivity in the US until 2035.
- Potential competitors may design different antibodies or formulations to circumvent the claims.
- The landscape suggests an ongoing patent race involving modifications like antibody humanization or conjugation to toxins or radioisotopes for enhanced efficacy.
- Biosimilars authorized or in development could challenge patent longevity or market share post-expiration.
Key Takeaways
- Patent 9,144,609 claims the specific amino acid sequences and methods for producing ipilimumab, a trailblazing immuno-oncology drug approved for melanoma.
- The patent scope is narrow but critical, covering the antibody itself, manufacturing methods, and therapeutic applications.
- The patent landscape is competitive, with multiple players filing patents on anti-CTLA-4 antibodies, including biosimilars and combination therapies.
- Patent expiration is anticipated in 2035, but ongoing innovation and filings could influence market exclusivity.
- Companies designing alternative anti-CTLA-4 agents must navigate these patents, either by designing around or licensing.
FAQs
Q1: Does patent 9,144,609 cover all anti-CTLA-4 antibodies?
No. It specifically claims the sequences related to ipilimumab. Similar antibodies with different sequences or modifications may not infringe unless they are considered equivalent under doctrine of equivalents.
Q2: Are there existing biosimilars to ipilimumab?
As of 2023, biosimilar applications have been filed and approved in some regions, but patent litigation or exclusivity periods impact market entry.
Q3: Can the methods of manufacturing described be used freely?
Not necessarily. The patent claims cover specific methods; using alternative methods may require licensing or result in infringement if equivalents are not carefully designed.
Q4: Are combination therapies protected under this patent?
Yes, the patent claims include methods combining ipilimumab with other agents, which can be infringed if the claimed methods are practiced.
Q5: How might future patents impact the use of ipilimumab?
Future patents could extend patent life if new formulations or methods are patented, or they might challenge existing patents' validity based on prior art or obviousness.
References
- U.S. Patent No. 9,144,609 (2015).
- FDA approval details for ipilimumab (Yervoy).
- Patent landscape reports from Clarivate and IAM Patent 1000.
- FDA Biosimilar approvals and patent litigations.
- Global patent filings related to anti-CTLA-4 antibodies.
